Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockMolecular Profile
Molecular Profile
Type
Synthetic peptidomimetic (modified tripeptide-like angiotensin IV analog)
Molecular formula
C27H44N4O5
Molecular weight
~504.66 g/mol
CAS number
1401708-83-5
Fatty acid chain
N-terminal hexanoyl cap (hexanoic acid)
Sequence
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Modification
N-terminal hexanoyl cap replacing the N-terminal residue of norleucine1-AngIV; C-terminal 6-aminohexanoic amide moiety replacing the His-Pro-Phe segment; designed to eliminate peptidase-sensitive bonds and increase metabolic stability and blood-brain-barrier permeance.
Mechanism & Target Class
Mechanism & Target Class
Dihexa is a peptidomimetic in the angiotensin IV (AngIV) analog class, engineered from norleucine1-angiotensin IV by retaining the Tyr-Ile pharmacophore identified as the procognitive core and replacing peptidase-labile termini with an N-terminal hexanoyl cap and a C-terminal 6-aminohexanoic amide. These modifications confer increased hydrophobicity, metabolic stability, and blood-brain-barrier permeability. Mechanistic studies proposed that Dihexa acts at the level of the hepatocyte growth factor (HGF)/c-Met receptor tyrosine kinase system — specifically at HGF dimerization and availability — with downstream readouts examined in PI3K/Akt and MAPK/ERK signaling. Historically, the parent AngIV system was associated with the AT4 binding site, later identified as insulin-regulated aminopeptidase (IRAP); the shift toward an HGF/c-Met framing is a contested element of the literature, and the key papers asserting direct HGF binding were subsequently retracted.
Storage & Handling
Storage & Handling
Lyophilized
Store dry and sealed
short term at 0–4 °C, long term at −20 °C.
Dry compound reported stable at ambient shipping temperatures for short periods. Batch molecular weight may vary with degree of hydration. For research use only.
References
References
Reviews
- 1
Hallberg M, et al. (2020). Frontiers in Pharmacology
- 2
Wright JW, Kawas LH, Harding JW. (2015). Progress in Neurobiology
Reviews
- 3
Wright JW, Harding JW. (2015). Journal of Alzheimer's Disease
- 4
Ho JK, Nation DA. (2018). Neurosci Biobehav Rev
- 5
Wright JW, Kawas LH, Harding JW. (2013). Front Endocrinol (Lausanne)
- 6
Wright JW, Harding JW. (2019). J Alzheimers Dis
Clinical
- 7
Hua X, Church K, Walker W, et al. (2022). Journal of Alzheimer's Disease
Primary research
- 8
Martino KA, Nakhre A, Demarest RM, Devilbiss DM. (2025). Neurotrauma Reports
- 9
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2025). Journal of Pharmacology and Experimental Therapeutics
- 10
Benoist CC, Kawas LH, Zhu M, et al. (2025). Journal of Pharmacology and Experimental Therapeutics
- 11
Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. (2021). Brain Sciences
- 12
Weiss JB, Phillips CJ, Malin EW, Gorantla VS, Harding JW, Salgar SK. (2021). Annals of Medicine and Surgery
- 13
Uribe PM, Kawas LH, Harding JW, Coffin AB. (2015). Frontiers in Cellular Neuroscience
- 14
Benoist CC, Kawas LH, Zhu M, et al. (2014). Journal of Pharmacology and Experimental Therapeutics
- 15
McCoy AT, Benoist CC, Wright JW, Kawas LH, et al. (2013). Journal of Pharmacology and Experimental Therapeutics
- 16
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. (2012). Journal of Pharmacology and Experimental Therapeutics
- 17
Kawas LH, Yamamoto BJ, Wright JW, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics
- 18
Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW. (2011). Journal of Pharmacology and Experimental Therapeutics
- 19
Yamamoto BJ, Elias PD, Masino JA, et al. (2010). Journal of Pharmacology and Experimental Therapeutics
- 20
Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. (2003). Journal of Neurochemistry
- 21
Albiston AL, McDowall SG, Matsacos D, et al. (2001). Journal of Biological Chemistry
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
